ReviewAmerican journal of cancer research2025
OTU deubiquitinases in cancer pathogenesis and precision therapy.
Review in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of deubiquitinating enzymes and their inhibitors in esophageal carcinoma (Review).International journal of oncology · 2026Review
- OTU deubiquitinases as immune-circuit editors: from human immunopathology to therapeutic prioritization.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The OTU family consists of 16 highly conserved deubiquitinases (DUBs) that play critical roles in regulating diverse signaling pathways through substrate-specific deubiquitination of key proteins. These enzymes are involved in multiple physiological processes, including cancer progression, immune responses, cell division, and inflammation modulation. Depending on their target substrates, individual OTU family members perform distinct functions across biological processes, as exemplified by their dual roles in cancer pathogenesis. Increasing attention has been directed toward developing OTU DUB inhibitors as potential cancer therapeutics. This review provides a systematic analysis of recent structural and functional studies on OTU family members, with a particular focus on their roles in cancer. We discuss their associations with various malignancies and summarize advances in OTU-targeted inhibitor development, emphasizing their clinical potential as novel therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.